MX2022013174A - Semaglutida para el tratamiento de la esteatohepatitis no alcoholica. - Google Patents

Semaglutida para el tratamiento de la esteatohepatitis no alcoholica.

Info

Publication number
MX2022013174A
MX2022013174A MX2022013174A MX2022013174A MX2022013174A MX 2022013174 A MX2022013174 A MX 2022013174A MX 2022013174 A MX2022013174 A MX 2022013174A MX 2022013174 A MX2022013174 A MX 2022013174A MX 2022013174 A MX2022013174 A MX 2022013174A
Authority
MX
Mexico
Prior art keywords
treatment
semaglutide
alcoholic steatohepatitis
glp
directed
Prior art date
Application number
MX2022013174A
Other languages
English (en)
Inventor
Martin Linder
Mads Sundby Palle
Lars Holm Damgaard
Morten Hansen
Carl Richard Torstenson
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2022013174A publication Critical patent/MX2022013174A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Inorganic Chemistry (AREA)

Abstract

La presente invención se dirige al uso del agonista del receptor de GLP-1 semaglutida en la terapia médica para el tratamiento de la esteatohepatitis no alcohólica.
MX2022013174A 2020-04-27 2021-04-26 Semaglutida para el tratamiento de la esteatohepatitis no alcoholica. MX2022013174A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20171536 2020-04-27
EP20173341 2020-05-06
PCT/EP2021/060827 WO2021219543A1 (en) 2020-04-27 2021-04-26 Semaglutide for the treatment of non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
MX2022013174A true MX2022013174A (es) 2022-11-30

Family

ID=75660049

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013174A MX2022013174A (es) 2020-04-27 2021-04-26 Semaglutida para el tratamiento de la esteatohepatitis no alcoholica.

Country Status (13)

Country Link
US (3) US11478533B2 (es)
EP (1) EP4142770A1 (es)
JP (1) JP7393563B2 (es)
KR (1) KR20230015884A (es)
CN (1) CN115461072A (es)
AU (1) AU2021262447A1 (es)
BR (1) BR112022020643A2 (es)
CA (1) CA3174964A1 (es)
CL (1) CL2022002813A1 (es)
IL (1) IL297273A (es)
MX (1) MX2022013174A (es)
TW (1) TW202140064A (es)
WO (1) WO2021219543A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3176613A1 (en) 2020-04-24 2021-10-28 Boehringer Ingelheim International Gmbh Glucagon analogues as long-acting glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CN118234742A (zh) * 2021-12-01 2024-06-21 江苏恒瑞医药股份有限公司 Glp-1和gip受体双重激动剂的药物组合物及其用途
CN114469877A (zh) * 2022-01-28 2022-05-13 兰州积石药业有限公司 一种司美格鲁肽植入剂及其制备方法
WO2024017139A1 (zh) * 2022-07-20 2024-01-25 成都海博为药业有限公司 一种含有glp-1受体激动剂类似物的药物组合物

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
EP1149066B1 (en) 1999-02-05 2005-11-09 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
EP1285914B1 (en) 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Nr1h4 nuclear receptor binding compounds
US20070010562A1 (en) 2001-08-13 2007-01-11 Ulrike Bauer Nr1h4 nuclear receptor binding compounds
EP1423113A4 (en) 2001-08-13 2007-04-18 Phenex Pharmaceuticals Ag NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
HUE038395T2 (hu) 2003-11-20 2018-10-29 Novo Nordisk As Propilén-glikol tartalmú peptidkészítmények, amelyek elõállításra és injekciós eszközökben történõ alkalmazásra optimálisak
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
US7544833B2 (en) 2006-09-07 2009-06-09 Hoffmann-La Roche Inc. Methods for producing N-(8-[2-hydroxybenzoyl]-amino) caprylic acid
AU2010212823B2 (en) 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
UA123760C2 (uk) 2011-11-11 2021-06-02 Гіліад Аполло, Ллс Сполука (варіанти) та композиція, що містить сполуку
WO2013068875A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. 2-thiopyrimidinones
AU2013245353A1 (en) 2012-04-06 2014-09-25 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors
WO2014182950A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
EP2994138A4 (en) 2013-05-10 2016-12-28 Nimbus Apollo Inc ACC-HEMMER AND USES THEREOF
CN105358154A (zh) 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
WO2014182951A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
AU2015233094B2 (en) 2014-03-17 2017-04-27 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
CA2962572A1 (en) 2014-09-24 2016-03-31 Gilead Sciences, Inc. Methods of treating liver disease with a combination of an ask1 inhibitor and a fxr agonist
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EA201892625A1 (ru) 2015-01-09 2019-07-31 Джилид Аполло, Ллс КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
CA3003465A1 (en) 2015-10-28 2017-05-04 Krishna Kumar Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
KR20180082556A (ko) 2015-11-25 2018-07-18 길리어드 아폴로, 엘엘씨 피라졸 acc 억제제 및 그의 용도
CN108347939B (zh) 2015-11-25 2021-09-28 吉利德阿波罗公司 含有2,4-二氧代-1,4-二氢噻吩并[2,3-d]嘧啶的衍生物的杀真菌组合物
MX2018006288A (es) 2015-11-25 2018-09-07 Gilead Apollo Llc Inhibidores de acc tipo ester y usos de los mismos.
JP2018536661A (ja) 2015-11-25 2018-12-13 ギリアド アポロ， エルエルシー トリアゾールａｃｃ阻害剤およびその使用
BR112018067408A2 (pt) 2016-03-02 2018-12-26 Gilead Apollo Llc formas sólidas de um inibidor de acc de tienopirimidinadiona e métodos para a produção das mesmas
RU2018140442A (ru) 2016-04-19 2020-05-18 Юрека Сарл Соединения пептидно-олигомочевинных фолдамеров и способы их применения
US20200397798A1 (en) 2016-05-25 2020-12-24 Akarna Therapeutics, Ltd. Combination therapies with farnesoid x receptor (fxr) modulators
CN115154467A (zh) 2016-06-03 2022-10-11 坎莫森特里克斯公司 治疗肝纤维化的方法
MX2018015443A (es) 2016-06-13 2019-04-11 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
AR108711A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
WO2018058109A1 (en) 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
US10588880B2 (en) 2016-09-28 2020-03-17 Eiger Biopharmaceuticals, Inc. Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
WO2018071528A1 (en) 2016-10-11 2018-04-19 University Of Georgia Research Foundation, Inc. Proteins and method for treating obesity and associated comorbidities
CA3042398A1 (en) 2016-11-11 2018-05-17 Gilead Sciences, Inc. Methods of treating liver disease
EP3573614A1 (en) 2017-01-27 2019-12-04 Genfit Pharmaceutical compositions for combination therapy
CN110382503B (zh) 2017-03-03 2022-07-19 吉利德科学公司 制备acc抑制剂及其固体形式的方法
MA49883A (fr) 2017-03-15 2021-04-21 Novo Nordisk As Composés bicycliques aptes à se lier au récepteur de mélanocortine 4
JP6906626B2 (ja) 2017-03-28 2021-07-21 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置するための治療的組み合わせ
CN110475556A (zh) 2017-03-28 2019-11-19 吉利德科学公司 治疗肝疾病的方法
TW201902478A (zh) 2017-04-12 2019-01-16 美商基利科學股份有限公司 治療肝臟疾病之方法
EP3612175A1 (en) 2017-04-18 2020-02-26 Genfit Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent
TW201908483A (zh) 2017-06-02 2019-03-01 新加坡商波濤生命科學有限公司 寡核苷酸組合物及其使用方法
WO2018231851A1 (en) 2017-06-13 2018-12-20 Gilead Sciences, Inc. Methods of treating liver fibrosis
WO2019018610A1 (en) 2017-07-19 2019-01-24 Bio-Rad Europe Gmbh COMBINATIONS OF BIOMARKERS FOR THE SIMULTANEOUS EVALUATION OF A NON ALCOHOLIC STHEATOHEPATITIS AND A STATE OF HEPATIC FIBROSIS
US11352405B2 (en) 2017-08-09 2022-06-07 Sanofi GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
TWI762706B (zh) 2017-08-24 2022-05-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
EP3691648A1 (en) 2017-10-06 2020-08-12 Gilead Sciences, Inc. Combination therapy comprising an acc inhibitor
KR20200110659A (ko) 2018-01-17 2020-09-24 더 유니버시티 오브 코네티컷 당뇨병, 간염 및/또는 염증성 간질환의 치료 방법
WO2019164799A1 (en) 2018-02-21 2019-08-29 Melior Pharmaceuticals I, Inc. Treatment of liver diseases
WO2019173505A1 (en) 2018-03-06 2019-09-12 Zafgen, Inc. Methods of treating disorders related to glycemic control
WO2019199642A1 (en) 2018-04-09 2019-10-17 Innovate Biopharmaceuticals Inc. Compositions and methods for treating or preventing hyperglycemia, insulin resistance, and associated organ damage
JP2021522247A (ja) 2018-04-24 2021-08-30 ピーエイチ・ファーマ・カンパニー・リミテッドＰｈ Ｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 肝疾患における好中球エラスターゼ阻害薬の使用
EP3787618A4 (en) 2018-05-04 2022-05-04 Cirius Therapeutics, Inc. THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES
MA52483A (fr) 2018-05-04 2021-03-10 Novo Nordisk As Dérivés de gip et leurs utilisations
US11081516B2 (en) 2018-08-10 2021-08-03 Guangdong Oppo Mobile Telecommunications Corp., Ltd. Display screen, electronic device and method for three-dimensional feature recognition
AU2019329884B2 (en) 2018-08-31 2022-01-27 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
SG11202103137WA (en) 2018-10-26 2021-04-29 Novo Nordisk As Stable semaglutide compositions and uses thereof
JP2022507644A (ja) 2018-11-16 2022-01-18 サイマベイ・セラピューティクス・インコーポレイテッド Ｎａｆｌｄおよびｎａｓｈの併用治療
MX2021005725A (es) 2018-11-16 2021-07-21 Cymabay Therapeutics Inc Tratamiento de la obesidad y sus complicaciones.
BR112021011762A2 (pt) 2019-01-15 2021-11-03 Gilead Sciences Inc Compostos para modulação de fxr (nr1h4)
AU2020225225B2 (en) 2019-02-19 2022-12-22 Gilead Sciences, Inc. Solid forms of FXR agonists
WO2020185686A1 (en) 2019-03-11 2020-09-17 Gilead Sciences, Inc. Formulations of a compound and uses thereof
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine

Also Published As

Publication number Publication date
EP4142770A1 (en) 2023-03-08
US11478533B2 (en) 2022-10-25
KR20230015884A (ko) 2023-01-31
US20230023012A1 (en) 2023-01-26
IL297273A (en) 2022-12-01
CL2022002813A1 (es) 2023-04-21
TW202140064A (zh) 2021-11-01
JP7393563B2 (ja) 2023-12-06
AU2021262447A1 (en) 2022-11-03
CA3174964A1 (en) 2021-11-04
US20240075106A1 (en) 2024-03-07
US20210330748A1 (en) 2021-10-28
BR112022020643A2 (pt) 2022-12-13
JP2023516505A (ja) 2023-04-19
CN115461072A (zh) 2022-12-09
WO2021219543A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
MX2022013174A (es) Semaglutida para el tratamiento de la esteatohepatitis no alcoholica.
MX2020005651A (es) Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
MY155255A (en) Spiro-oxindole compounds and their use as therapeutic agents
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
TWD196868S (zh) 超音波治療手持件
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
MX2017013142A (es) Terapia combinada para tratar cáncer.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2021004708A (es) Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares.
PH12016502353A1 (en) Pharmaceutical composition
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
TW201613577A (en) Pharmaceutical combinations
MX2010002178A (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico.
PH12019501528A1 (en) Combination therapy for nonalcoholic steatohepatitis (nash) and liver fibrosis
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
PH12021550448A1 (en) Chronic nightly dosing of lasmiditan for migraine prevention.
MX2019014665A (es) Nuevos derivados de azaindolina sustituida como inhibidores de nik.
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2023004796A (es) Compuestos, composiciones y metodos de uso para tratar fracturas oseas.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2020013601A (es) Receptores de las celulas t especificos de cancer.